nice tirzepatide obesity Rolling out for weight management: NHS England recommendations NICE outlines weight loss drug

Always consult a healthcare provider before considering a medication switch

It is the difference between losing fat and muscle (bad) versus losing primarily fat while preserving or even building muscle (good)

Novel dual incretin agonist peptide with antidiabetic and neuroprotective potential

[6] With Foundayo, Wegovy, and Zepbound all readily available in 2026, the prior shortage rationale for compounding has largely disappeared

suggesting its detrimental effect on kidney health

Dual-Hormone Action on Appetite Tirzepatide activates both GLP-1 and GIP receptors in the brain, leading to a stronger reduction in hunger and food cravings than single-agonist drugs